Halozyme Therapeutics (NASDAQ: HALO) is one of 288 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Halozyme Therapeutics to related businesses based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a summary of current ratings for Halozyme Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics 1 2 4 0 2.43
Halozyme Therapeutics Competitors 1377 4466 12285 311 2.63

Halozyme Therapeutics presently has a consensus price target of $16.29, indicating a potential upside of 0.22%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 34.53%. Given Halozyme Therapeutics’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Halozyme Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Halozyme Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Halozyme Therapeutics -89.43% N/A -43.03%
Halozyme Therapeutics Competitors -4,766.65% -354.93% -43.41%

Valuation & Earnings

This table compares Halozyme Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Halozyme Therapeutics $134.17 million -$95.85 million -17.47
Halozyme Therapeutics Competitors $464.68 million $167.54 million -6.57

Halozyme Therapeutics’ competitors have higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

85.1% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 51.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.8% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Halozyme Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics’ competitors have a beta of 6.57, suggesting that their average stock price is 557% more volatile than the S&P 500.

Summary

Halozyme Therapeutics competitors beat Halozyme Therapeutics on 8 of the 12 factors compared.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant. The Company’s development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.